NDRA (ENDRA Life Sciences) Risk Assessment

View and export this data going back to 2017. Start your Free Trial

What is ENDRA Life Sciences Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of ENDRA Life Sciences is: No Data: Cannot be evaluated.

Competitive Comparison of ENDRA Life Sciences's Risk Assessment

For the Diagnostics & Research subindustry, ENDRA Life Sciences's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ENDRA Life Sciences's Risk Assessment Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, ENDRA Life Sciences's Risk Assessment distribution charts can be found below:

* The bar in red indicates where ENDRA Life Sciences's Risk Assessment falls into.

Save Embed

;

Save Embed

;

ENDRA Life Sciences (NAS:NDRA) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

ENDRA Life Sciences Risk Assessment Related Terms

Thank you for viewing the detailed overview of ENDRA Life Sciences's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

ENDRA Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » ENDRA Life Sciences Inc (NAS:NDRA) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

3600 Green Court, Suite 350, Ann Arbor, MI, USA, 48105-1570

Website

https://www.endrainc.com

ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.

Executives

Michael Milos Thornton	officer: Chief Technology Officer	3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105
Anthony Digiandomenico	director	3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105
Alexander Y Tokman	director	C/O MICROVISION, INC., 6222 185TH AVENUE NE, REDMOND WA 98052
Francois Roger Michelon	director, officer: Chief Executive Officer	430 N. JUNO LANE, JUNO BEACH FL 33406
Lou Basenese	director	3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105
Irina Pestrikova	officer: Senior Director, Finance	3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105
Renaud Bertrand Maloberti	officer: Chief Commercial Officer	10 ACORN WAY, GEORGETOWN MA 01833
David R. Wells	officer: Chief Financial Officer	2801 OCEAN PARK BLVD., SUITE 339, SANTA MONICA CA 90405
Michael Harsh	director	3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105
Longboard Capital Advisors, Llc	10 percent owner	9665 WILSHIRE BLVD., SUITE 430, BEVERLY HILLS CA 90212
Brett Conrad	10 percent owner	1312 CEDAR ST., SANTA MONICA CA 90405
Sanjiv Sam Gambhir	director	3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105